The monosodium glutamate symptom complex: Assessment in a double-blind, placebo-controlled, randomized study

被引:85
|
作者
Yang, WH
Drouin, MA
Herbert, M
Mao, Y
Karsh, J
机构
[1] UNIV OTTAWA, DEPT MED, OTTAWA, ON, CANADA
[2] HLTH CANADA, LAB CTR DIS CONTROL, OTTAWA, ON K1A 0L2, CANADA
[3] HLTH CANADA, BUR CHRON DIS EPIDEMIOL, OTTAWA, ON K1A 0L2, CANADA
关键词
monosodium glutamate; monosodium glutamate symptom complex; randomized double-blind challenge;
D O I
10.1016/S0091-6749(97)80008-5
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Considerable debate swirls about the validity of symptoms described by many people after ingestion of monosodium glutamate (MSG), and the question has remained unresolved largely because of a paucity of well-designed challenge studies. Methods: We conducted oral challenge studies in self-identified MSG-sensitive subjects to determine whether they had a statistically significant difference in the incidence of their specific symptoms after ingestion of MSG compared with placebo. First, 5 gm MSG or placebo was administered in random sequence in a double-blind fashion. Subjects who reacted only to a single test agent then underwent rechallenge in random sequence in a double-blind fashion with placebo and 1.25, 2.5, and 5 gm MSG. A positive response to challenge was defined as the reproduction of greater than or equal to 2 of the specific symptoms in a subject ascertained on prechallenge interview. Results: Sixty-one subjects entered the study. On initial challenge, 18 (29.5%) responded to neither MSG nor placebo, 6 (9.8%) to both, 15 (24.6%) to placebo, and 22 (36.1%) to MSG (p = 0.324). Total and average severity of symptoms after ingestion of MSG (374 and 80) were greater than respective values after placebo ingestion (232 and 56; p = 0.026 and 0.018, respectively). Rechallenge revealed an apparent threshold dose for reactivity of 2.5 gm MSG. Headache (p < 0.023), muscle tightness (p < 0.004), numbness/tingling (p < 0.007), general weakness (p < 0.040), and Bushing (p < 0.016) occurred more frequently after MSG than placebo ingestion. Conclusions: Oral challenge with MSG reproduced symptoms in alleged sensitive persons. The mechanism of the reaction remains unknown, but symptom characteristics do not support an IgE-mediated mechanism. According to Food and Drug Administration recommendations, the symptoms, originally called the Chinese restaurant syndrome, are better referred to as the MSG symptom complex.
引用
收藏
页码:757 / 762
页数:6
相关论文
共 50 条
  • [31] Pentoxifylline in severe sepsis: a double-blind, randomized placebo-controlled study
    KH Staubach
    J Schröder
    P Zabel
    F Stüber
    Critical Care, 2 (Suppl 1):
  • [32] SULFASALAZINE IN SPONDYLARTHROPATHY - A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    DOUGADOS, M
    VANDERLINDEN, S
    LEIRISALOREPO, M
    HUITFELDT, B
    BERTOUCH, J
    BROOKS, P
    DIJKMANS, B
    EDMONDS, J
    MAJOR, G
    KVIEN, T
    OLIVIERI, I
    VEYS, E
    ZEIDLER, H
    AMOR, B
    CALIN, A
    ARTHRITIS AND RHEUMATISM, 1993, 36 (09): : S92 - S92
  • [33] Risperidone in children with autism: Randomized, placebo-controlled, double-blind study
    Nagaraj, Ravishankar
    Singhi, Pratibha
    Malhi, Prahbhjot
    JOURNAL OF CHILD NEUROLOGY, 2006, 21 (06) : 450 - 455
  • [34] Double-blind, placebo-controlled study of quetiapine
    Chawla, J. M.
    BIPOLAR DISORDERS, 2008, 10 : 42 - 42
  • [35] HEMODYNAMIC ASSESSMENT OF SOTALOL AND QUINIDINE - A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL
    MAHMARIAN, J
    VERANI, M
    THORNTON, B
    HILLEMMETT, R
    BOLLI, R
    PRATT, C
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1987, 10 (04): : 1000 - 1000
  • [36] The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study
    Harsini, Sara
    Saprunoff, Heather
    Alden, Tina
    Mohammadi, Behnoud
    Wilson, Don
    Benard, Francois
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (01) : 81 - 87
  • [37] Marfan Sartan: a randomized, double-blind, placebo-controlled trial
    Milleron, Olivier
    Arnoult, Florence
    Ropers, Jacques
    Aegerter, Philippe
    Detaint, Delphine
    Delorme, Gabriel
    Attias, David
    Tubach, Florence
    Dupuis-Girod, Sophie
    Plauchu, Henry
    Barthelet, Martine
    Sassolas, Francois
    Pangaud, Nicolas
    Naudion, Sophie
    Thomas-Chabaneix, Julie
    Dulac, Yves
    Edouard, Thomas
    Wolf, Jean-Eric
    Faivre, Laurence
    Odent, Sylvie
    Basquin, Adeline
    Habib, Gilbert
    Collignon, Patrick
    Boileau, Catherine
    Jondeau, Guillaume
    EUROPEAN HEART JOURNAL, 2015, 36 (32) : 2160 - U37
  • [38] A double-blind, randomized, placebo-controlled laser trial methodology
    Oussedik, E.
    Saleem, M. D.
    Patel, N. U.
    Feldman, S. R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : B11 - B11
  • [39] A randomized, double-blind, placebo-controlled trial of pseudoephedrine in coryza
    Latte, J
    Taverner, D
    Slobodian, P
    Shakib, S
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2004, 31 (07): : 429 - 432
  • [40] A randomized, double-blind, placebo-controlled study of olanzapine in patients with bipolar depression
    Tohen, M.
    McDonnell, D. P.
    Case, M.
    Kanba, S.
    Ha, K.
    Fang, Y.
    Katagiri, H.
    Gomez, J. C.
    BIPOLAR DISORDERS, 2011, 13 : 100 - 100